CSRT.L Regulatory News (CSRT)

News Release

15 September 2010

Consort Medical plc

Interim Management Statement

Consort Medical plc (LSE: CSRT), today issues its interim management statement for the period from 1 May to date.

Bespak has enjoyed a good start to the year, in particular in the Respiratory business, with valve volumes recovering well following earlier customer destocking. We have made good progress with our development pipeline.

King Systems has also made an encouraging start to the year, with underlying revenue growth supported by a strong order book carried over from the previous year. The manufacturing transformation and new product development programmes are progressing as previously forecast.

There has been no significant change in the Group's financial position since the publication of the Group's preliminary results for the year ended 30 April 2010 in June 2010. The Group remains strongly cash generative.

The Board remains confident about the outlook for the full year.

For enquiries, please contact:

Consort Medical plc is a leader in medical devices for inhaled drug delivery, self-injection and anaesthesia. The Group develops drug delivery systems for the pharmaceutical industry and disposable airway management products for critical care settings in hospitals.

Consort Medical develops and manufactures metered dose inhaler valves, actuators, compliance aids, dry powder devices autoinjectors, disposable facemasks, breathing circuits and laryngeal tubes. The Group has facilities in King's Lynn, Sheffield, Nelson and Hemel Hempstead in the UK, and Indianapolis, Indiana and Kent, Ohio in the US. Consort Medical is a public company quoted on the full list of the London Stock Exchange (LSE: CSRT).